Abstract
Most of the vaccine strategies under development use multiple immunizations with the same agent such as a viral vector encoding a tumor antigen. More recently, the concept of heterologous prime-boost immunization has been tested in animal models. This strategy involves the sequential administration of different delivery vectors encoding the same recombinant antigen (1). Initially demonstrated in animal studies of infectious diseases, such as malaria (1,2) and AIDS (3), prime-boost technology is now being developed for use in tumor patients (4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Li S, Rodrigues M, Rodriguez D, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993; 90:5214–5218.
Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4:397–402.
Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69–74.
Palmowski MJ, Choi EM, Hermans IF, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168:4391–4398.
Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964–3973.
Oertli D, Marti WR, Zajac P, et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 2002; 13:569–575.
Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998; 8:683–691.
Flynn KJ, Riberdy JM, Christensen JP, Altman JD, Doherty PC. In vivo proliferation of naive and memory influenza-specific CD8(+) T cells. Proc Natl Acad Sci USA 1999; 96:8597–8602.
Crowe JE, Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001; 33:1720–1727.
McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Onirol 1996. 1.495–500
Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21:163–165.
Mateo L, Gardner J, Chen Q, et al. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 1999; 163:4058–4063.
Kedl RM, Rees WA, Hildeman DA, et al. T cells compete for access to antigen-bearing antigenpresenting cells. J Exp Med 2000; 192:1105–1113.
Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51–88.
Sandberg JK, Grufman P, Wolpert EZ, Franksson L, Chambers BJ, Karre K. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. J Immunol 1998; 160:3163–3169.
Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunitv. Cancer Res 2002; 62:6944–6951.
Pasquini S, Peralta S, Missiaglia E, Carta L, Lemoine NR. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther 2002; 9:503–510.
Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001; 61:8782–8786.
Tuettenberg A, Jonuleit H, Tuting T, Bruck J, Knop J, Enk AH. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumorspecific CD8(+) T cells: implications for an efficient vaccination strategy. Gene Ther 2003; 10:243–250.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this chapter
Cite this chapter
Palmowski, M.J., Smith, C. (2004). Heterologous Prime-Boost Vaccination in Tumor Immunotherapy. In: Morse, M.A., Clay, T.M., Lyerly, H.K. (eds) Handbook of Cancer Vaccines. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-680-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-680-5_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9818-9
Online ISBN: 978-1-59259-680-5
eBook Packages: Springer Book Archive